Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC grew its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 72.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,198,689 shares of the medical equipment provider's stock after buying an additional 2,610,118 shares during the period. Janus Henderson Group PLC owned approximately 8.92% of Lantheus worth $554,583,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus during the 3rd quarter valued at $25,000. Kestra Investment Management LLC purchased a new position in shares of Lantheus during the 4th quarter valued at about $27,000. Summit Securities Group LLC purchased a new position in Lantheus in the 4th quarter worth approximately $37,000. UMB Bank n.a. increased its stake in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares during the period. Finally, Parkside Financial Bank & Trust increased its stake in Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after purchasing an additional 280 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on LNTH. Truist Financial reduced their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. StockNews.com raised Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, B. Riley reduced their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $132.67.

Lantheus Stock Performance

Shares of LNTH stock traded up $1.46 during trading hours on Friday, reaching $81.24. The company had a trading volume of 913,841 shares, compared to its average volume of 981,309. The stock has a fifty day moving average of $97.57 and a 200-day moving average of $93.51. The company has a market capitalization of $5.56 billion, a price-to-earnings ratio of 13.52 and a beta of 0.23. Lantheus Holdings, Inc. has a 12-month low of $75.00 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same quarter in the previous year, the business posted $1.69 earnings per share. The firm's revenue was up .8% on a year-over-year basis. On average, analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. The trade was a 10.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 63,109 shares of company stock valued at $6,016,046. 1.50% of the stock is currently owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.